Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis and Metrics

Supernus Pharmaceuticals

NASDAQ: SUPN

$46.21 ▼ -0.98 (-2.09%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.67 Bn

P/E-99.88

Div. Yield0.00

Add ratio to table…

About

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of treatments for central nervous system (CNS) diseases. The company focuses on a diverse neuroscience portfolio, including approved therapies for attention-deficit hyperactivity disorder (ADHD), Parkinson’s disease (PD), postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Supernus also advances a pipeline of novel product candidates targeting various CNS disorders, leveraging proprietary formulation technologies to enhance efficacy, improve patient adherence, and reduce side effects. The company’s strategic acquisitions, such as the 2025 purchase of Sage Therapeutics, Inc., have expanded its portfolio and commercial capabilities, particularly in the treatment of depression and other neuropsychiatric conditions.

Supernus Pharmaceuticals, Inc. generates revenue primarily through the sale of its proprietary CNS drugs in the U. S. market, with additional income derived from licensing agreements, royalties, and collaborations for international commercialization. Key commercial products include Qelbree for ADHD, GOCOVRI for dyskinesia and "OFF" episodes in Parkinson’s disease, ZURZUVAE for postpartum depression, and Trokendi XR and Oxtellar XR for epilepsy and migraine prevention. The company also markets APOKYN and ONAPGO for hypomobility in Parkinson’s disease, XADAGO for "OFF" episodes, MYOBLOC for cervical dystonia and chronic sialorrhea, and Osmolex ER. Revenue is further bolstered by milestone payments and royalties from partnerships, such as its collaboration with Biogen for ZURZUVAE and licensing agreements with Shionogi for zuranolone in Japan, South Korea, and Taiwan. The majority of sales are made to pharmaceutical wholesalers, specialty pharmacies, and distributors, which then supply healthcare providers and patients.

The company operates through the following segments:

• Neurology: This segment focuses on the development and commercialization of treatments for neurological disorders, including Parkinson’s disease and epilepsy. Key products include GOCOVRI, APOKYN, ONAPGO, XADAGO, Trokendi XR, and Oxtellar XR. The segment also encompasses the company’s proprietary technologies, such as Microtrol, Solutrol, and EnSoTrol, which are used to enhance drug formulations and improve patient outcomes. Supernus markets these products through specialized sales forces targeting movement disorder specialists, neurologists, and other healthcare providers.

• Psychiatry: This segment is dedicated to psychiatric conditions, including ADHD and postpartum depression. Leading products include Qelbree for ADHD and ZURZUVAE for PPD, the latter of which is co-commercialized with Biogen in the U. S. The segment also includes pipeline candidates like SPN-820 for treatment-resistant depression and SPN-443 for ADHD. Sales efforts are directed toward psychiatrists, pediatricians, primary care physicians, obstetricians-gynecologists, and advanced practice providers. The acquisition of Sage Therapeutics significantly strengthened this segment by adding zuranolone-based therapies and expanding the company’s footprint in depression and neuropsychiatric disorders.

Supernus Pharmaceuticals, Inc. holds a competitive position in the CNS therapeutics market, distinguished by its focus on underserved and complex neurological and psychiatric conditions. In ADHD, Qelbree competes with both stimulant and non-stimulant therapies, including generics like Adderall XR and Vyvanse, as well as branded products such as Intuniv and Strattera. Its non-stimulant profile and once-daily dosing provide a differentiated option for patients and prescribers. In Parkinson’s disease, GOCOVRI is the only FDA-approved treatment for both dyskinesia and "OFF" episodes, positioning it uniquely against competitors like Inbrija and NOURIANZ. The company’s epilepsy and migraine portfolio, led by Trokendi XR and Oxtellar XR, benefits from extended-release formulations that improve adherence and tolerability compared to immediate-release alternatives. ZURZUVAE, the first oral treatment for postpartum depression, faces competition from standard antidepressants but offers a rapid, 14-day treatment course, a significant advantage in this underserved market. Supernus’s proprietary technologies and strategic partnerships further enhance its competitive edge by enabling the development of novel formulations and expanding global reach.

Supernus Pharmaceuticals, Inc. serves a broad customer base, primarily through pharmaceutical wholesalers, specialty pharmacies, and distributors. Its three largest customers—Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation—collectively accounted for over 76% of total product revenue in 2025. These intermediaries supply the company’s products to pharmacies, hospitals, and other healthcare providers, including federal and state entities. Direct sales to physicians and hospitals are also a component of its distribution model, particularly for products like MYOBLOC. The company’s commercial efforts target specialized healthcare providers, such as movement disorder specialists for Parkinson’s therapies, psychiatrists and pediatricians for ADHD treatments, and obstetricians-gynecologists for postpartum depression therapies. Through collaborations with partners like Biogen and Shionogi, Supernus also reaches international markets, extending its customer base beyond the U. S.

Investment Thesis

▲ Bull case

Supernus Pharmaceuticals demonstrates robust momentum across its core growth portfolio, with Onepco showing a clear rebound trajectory following supply constraint resolution, as evidenced by March 2026 prescriptions reaching 463—exceeding pre-constraint October 2025 levels—and prescriber shipments hitting their highest since launch, signaling restored operational capacity and accelerating patient adoption that management may be under-communicating given their conservative guidance range of $45 million to $70 million for the product in 2026, which appears low relative to the 2,200 enrollment forms submitted through April 2026 and a backlog of approximately 570 patients in queue, suggesting meaningful upside if conversion rates stabilize near historical levels and processing efficiency continues to improve post-February restart.
The collaboration revenue stream from ZERZUVEX, particularly the $20 million licensing milestone achieved under the Shinobi agreement in Q1 2026, represents a significantly underappreciated catalyst for financial flexibility, as this non-recurring inflow directly bolsters the $384 million cash position (up from $309 million at year-end 2025) and supports the company’s stated priority for revenue-generating M&A, yet management did not emphasize how such milestone-driven cash could enable strategic acquisitions of late-stage CNS assets without dilution, creating a hidden pathway to accelerate pipeline value realization beyond organic growth.
XERZUVEY’s prescription growth of approximately 100% year-over-year in Q1 2026, coupled with 85% of prescriptions originating from routine prescribers and over 29,000 patients treated since launch, reveals a deeply entrenched adoption pattern in the postpartum depression market that management characterizes as still being in the “early innings,” but the data suggests rapid penetration into a sizable addressable population of ~500,000 annual sufferers, with low relapse rates indicating durable initial uptake and potential for expanded labeling or dosing regimens to unlock multi-cycle use, a structural shift the market may overlook due to the product’s current single-cycle framing.
Caleri’s accelerating adult prescription growth of 27% year-over-year in Q1 2026, coupled with the first-time surpassing of adult prescribers over pediatric prescribers, signals a durable secular shift toward broader ADHD market penetration that management attributes to seasonal focus but fails to fully connect to the product’s unique full-day coverage advantage over stimulants—a differentiation gaining traction among adult patients intolerant to or requiring supplemental doses with stimulants, which could drive sustained market share gains in the largest and fastest-growing ADHD segment, yet this thesis remains under-discussed in favor of quarterly volatility narratives.
The company’s zero-debt balance sheet and strong cash generation, highlighted by CFO Timothy C. Dec’s emphasis on financial flexibility for M&A, presents a structural advantage in a consolidating CNS landscape where peers face leverage constraints, yet management did not explicitly link this position to the ability to pursue opportunistic bolt-on acquisitions of late-stage assets during periods of market dislocation, a strategic lever that could meaningfully enhance long-term growth profile beyond current guidance ranges.

Supernus Pharmaceuticals demonstrates robust momentum across its core growth portfolio, with Onepco showing a clear rebound trajectory following supply constraint resolution, as evidenced by March 2026 prescriptions reaching 463—exceeding pre-constraint October 2025 levels—and prescriber shipments hitting their highest since launch, signaling restored operational capacity and accelerating patient adoption that management may be under-communicating given their conservative guidance range of $45 million to $70 million for the product in 2026, which appears low relative to the 2,200 enrollment forms submitted through April 2026 and a backlog of approximately 570 patients in queue, suggesting meaningful upside if conversion rates stabilize near historical levels and processing efficiency continues to improve post-February restart.
The collaboration revenue stream from ZERZUVEX, particularly the $20 million licensing milestone achieved under the Shinobi agreement in Q1 2026, represents a significantly underappreciated catalyst for financial flexibility, as this non-recurring inflow directly bolsters the $384 million cash position (up from $309 million at year-end 2025) and supports the company’s stated priority for revenue-generating M&A, yet management did not emphasize how such milestone-driven cash could enable strategic acquisitions of late-stage CNS assets without dilution, creating a hidden pathway to accelerate pipeline value realization beyond organic growth.
XERZUVEY’s prescription growth of approximately 100% year-over-year in Q1 2026, coupled with 85% of prescriptions originating from routine prescribers and over 29,000 patients treated since launch, reveals a deeply entrenched adoption pattern in the postpartum depression market that management characterizes as still being in the “early innings,” but the data suggests rapid penetration into a sizable addressable population of ~500,000 annual sufferers, with low relapse rates indicating durable initial uptake and potential for expanded labeling or dosing regimens to unlock multi-cycle use, a structural shift the market may overlook due to the product’s current single-cycle framing.
Caleri’s accelerating adult prescription growth of 27% year-over-year in Q1 2026, coupled with the first-time surpassing of adult prescribers over pediatric prescribers, signals a durable secular shift toward broader ADHD market penetration that management attributes to seasonal focus but fails to fully connect to the product’s unique full-day coverage advantage over stimulants—a differentiation gaining traction among adult patients intolerant to or requiring supplemental doses with stimulants, which could drive sustained market share gains in the largest and fastest-growing ADHD segment, yet this thesis remains under-discussed in favor of quarterly volatility narratives.
The company’s zero-debt balance sheet and strong cash generation, highlighted by CFO Timothy C. Dec’s emphasis on financial flexibility for M&A, presents a structural advantage in a consolidating CNS landscape where peers face leverage constraints, yet management did not explicitly link this position to the ability to pursue opportunistic bolt-on acquisitions of late-stage assets during periods of market dislocation, a strategic lever that could meaningfully enhance long-term growth profile beyond current guidance ranges.

▼ Bear case

Supernus Pharmaceuticals’ guidance for Onepco remains range-bound at $45 million to $70 million for full-year 2026 despite a launch-to-date backlog of 2,200 enrollment forms and improving processing metrics, reflecting persistent uncertainty around patient conversion rates and persistence that management acknowledged as still early-stage, with Khattar noting a 40% to 45% drop-off from form to shipment due to insurance issues, incomplete documentation, and lack of patient follow-through—risks exacerbated by the product’s complex titration requirements for apomorphine, which could sustain lower-than-expected real-world adherence and limit revenue conversion even as demand indicators improve.
The apparent strength in XERZUVEY’s 100% year-over-year prescription growth in Q1 2026 may be misleading due to a low base effect from minimal 2025 sales, and management’s own admission that only 29,000 patients have been treated since launch—far below the 500,000 annual addressable population—suggests limited penetration depth, while the product’s inherent nature as a short-term, non-recurring therapy (dependent on repeat pregnancies) creates a structural ceiling on recurring revenue potential that the market may be overestimating as a durable growth driver, particularly given the lack of meaningful DTC campaign impact data to date.
Caleri’s adult-focused growth narrative, while positive, faces increasing competition from novel non-stimulant and multimodal ADHD therapies in late-stage development, and management’s emphasis on serotonin modulation and comorbidities as growth avenues remains speculative without clinical validation in current trials, raising the risk that the product’s differentiation—such as once-daily full-day coverage—could be eroded by emerging alternatives offering similar convenience with superior efficacy or safety profiles, a threat not adequately addressed in the Q&A despite acknowledgment of a broadening patient profile.
R&D productivity remains a concern, as the pipeline updates provided—SPN-820 for MDD, SPN-817 for treatment-resistant seizures, and SPN-443 for ADHD—are all in early-to-mid phase stages (Phase 2b or planned Phase 1), with no near-term catalysts expected before 2027, yet SG&A expenses rose sharply due to Biogen collaboration costs, increasing combined R&D and SG&A to $164.6 million in Q1 2026 from $116.9 million year-over-year, suggesting inefficient scaling of commercial infrastructure that could pressure margins if pipeline progress stalls and royalty-dependent revenue streams like the Shinobi milestone fail to repeat.
The company’s reliance on collaboration and licensing revenue, exemplified by the $20 million Shinobi milestone in Q1 2026, introduces volatility into earnings quality, as such one-time items are non-recurring and not indicative of sustainable operational performance, yet management’s reiteration of full-year 2026 guidance for non-GAAP operating earnings ($140 million to $170 million) appears to assume continued milestone-driven inflows without disclosing the probability or timing of similar events, creating a risk that investors may be overestimating the predictability of earnings strength absent guaranteed near-term pipeline approvals or commercial deals.

Supernus Pharmaceuticals’ guidance for Onepco remains range-bound at $45 million to $70 million for full-year 2026 despite a launch-to-date backlog of 2,200 enrollment forms and improving processing metrics, reflecting persistent uncertainty around patient conversion rates and persistence that management acknowledged as still early-stage, with Khattar noting a 40% to 45% drop-off from form to shipment due to insurance issues, incomplete documentation, and lack of patient follow-through—risks exacerbated by the product’s complex titration requirements for apomorphine, which could sustain lower-than-expected real-world adherence and limit revenue conversion even as demand indicators improve.
The apparent strength in XERZUVEY’s 100% year-over-year prescription growth in Q1 2026 may be misleading due to a low base effect from minimal 2025 sales, and management’s own admission that only 29,000 patients have been treated since launch—far below the 500,000 annual addressable population—suggests limited penetration depth, while the product’s inherent nature as a short-term, non-recurring therapy (dependent on repeat pregnancies) creates a structural ceiling on recurring revenue potential that the market may be overestimating as a durable growth driver, particularly given the lack of meaningful DTC campaign impact data to date.
Caleri’s adult-focused growth narrative, while positive, faces increasing competition from novel non-stimulant and multimodal ADHD therapies in late-stage development, and management’s emphasis on serotonin modulation and comorbidities as growth avenues remains speculative without clinical validation in current trials, raising the risk that the product’s differentiation—such as once-daily full-day coverage—could be eroded by emerging alternatives offering similar convenience with superior efficacy or safety profiles, a threat not adequately addressed in the Q&A despite acknowledgment of a broadening patient profile.
R&D productivity remains a concern, as the pipeline updates provided—SPN-820 for MDD, SPN-817 for treatment-resistant seizures, and SPN-443 for ADHD—are all in early-to-mid phase stages (Phase 2b or planned Phase 1), with no near-term catalysts expected before 2027, yet SG&A expenses rose sharply due to Biogen collaboration costs, increasing combined R&D and SG&A to $164.6 million in Q1 2026 from $116.9 million year-over-year, suggesting inefficient scaling of commercial infrastructure that could pressure margins if pipeline progress stalls and royalty-dependent revenue streams like the Shinobi milestone fail to repeat.
The company’s reliance on collaboration and licensing revenue, exemplified by the $20 million Shinobi milestone in Q1 2026, introduces volatility into earnings quality, as such one-time items are non-recurring and not indicative of sustainable operational performance, yet management’s reiteration of full-year 2026 guidance for non-GAAP operating earnings ($140 million to $170 million) appears to assume continued milestone-driven inflows without disclosing the probability or timing of similar events, creating a risk that investors may be overestimating the predictability of earnings strength absent guaranteed near-term pipeline approvals or commercial deals.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password